Novavax COVID-19 vaccine to be included in combo vaccine study

By The Science Advisory Board staff writers

Novavax announced it will participate in a newly expanded phase II trial to study NVX-CoV2373, its recombinant protein COVID-19 vaccine candidate. The candidate vaccine is one of four that will be studied to evaluate the potential for combined regimens that mix vaccines from different manufacturers to achieve immune protection against COVID-19.

The "Com-COV2" study will include 1,050 adults 50 years of age or older who received their first vaccination during the prior eight to 12 weeks. Volunteer study participants will receive one of four different vaccines as a second dose, 350 of whom will be administered NVX-CoV2373. The research will compare the immune system responses from those who receive a heterologous regimen to those who receive a homologous regimen.

In addition, NVX-CoV2373 continues to be evaluated in phase III trials, one in the U.K that demonstrated efficacy of 96.4% against the original strain of SARS-CoV-2 and 89.7% overall, and one in the U.S. and Mexico (the Prevent-19 trial) that began in December 2020. It is also being tested in two ongoing phase II studies that began in August 2020: a phase IIB trial in South Africa that demonstrated 48.6% efficacy against a newly emerging escape variant, and a phase I/II continuation in the U.S. and Australia.


Copyright © 2021 scienceboard.net
 

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?